| Name | Title | Contact Details |
|---|
Titan Spine is a surface technology company that produces the only FDA-cleared nanotechnology interbody fusion devices that participate in the spinal fusion process.
ZipLine® Medical is developing and commercializing innovative tissue repair devices to address the clinical need for rapid, non-invasive and easy-to-use skin closure. ZipLine`s PRELOC™ technology platform provides uniform closure forces while minimizing scar-promoting tension along the wound. Utilizing our patented technology, we believe that physicians can achieve the best of both worlds — the speed of staples with the cosmetic outcome of a meticulous suture closure. Our initial strategy focuses on procedures where the non-invasive, speed and cosmetic benefits of our technology have the greatest impact. Since skin closure is a part of most surgical procedures, our technology platform has broad application across various surgical specialties and emergency medicine. ZipLine Medical was founded in 2009 by Amir Belson, M.D. and is located in Silicon Valley, with access to a wealth of expertise in medical device research and development
A publicly traded (OTC: CBSC) company providing innovative products and services in the ambulatory non-invasive cardiac monitoring space. CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
High Technology is a Walpole, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Milford, Massachusetts, RenalGuard Solutions, Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard`s effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA. The RenalGuard System™ consists of a closed loop, software-controlled console and single-use sets that physicians and nurses use for automated matched fluid replacement to minimize over- or under-hydration of patients during medical procedures where creating and maintaining high urine outputs is beneficial.